GSK's Hal Barron with Endpoints founder John Carroll / Credit: Endpoints News

A GSK-led con­sor­tium looks to break ground with a new class of an­tibi­ot­ic, push­ing in­to a piv­otal

Af­ter watch­ing a slew of biotechs crash and burn af­ter field­ing a line­up of fresh­ly ap­proved an­tibi­otics, Glax­o­SmithK­line is hop­ing to achieve some­thing new in the field. The phar­ma gi­ant, backed by some big pub­lic part­ners, has com­menced the first of two large Phase III large clin­i­cal tri­als for an ex­per­i­men­tal an­tibi­ot­ic gepoti­dacin, tar­get­ing 2 in­fec­tions that haven’t seen a new oral an­tibi­ot­ic in more than 20 years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.